Boston Scientific CorporationBSXNYSE
Loading
Net Income Growth Under PressureDecelerating
Percentile Rank38
Year-over-Year Change
Year-over-year net income growth rate
Percentile
P38
Within normal range
vs 5Y Ago
-0.1x
Contraction
Streak
5 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -11.52% |
| Q3 2025 | -4.79% |
| Q2 2025 | 17.66% |
| Q1 2025 | 19.08% |
| Q4 2024 | 20.68% |
| Q3 2024 | 44.75% |
| Q2 2024 | -34.41% |
| Q1 2024 | -1.98% |
| Q4 2023 | 0.00% |
| Q3 2023 | 86.67% |
| Q2 2023 | -14.01% |
| Q1 2023 | 124.29% |
| Q4 2022 | -25.53% |
| Q3 2022 | -27.69% |
| Q2 2022 | 134.23% |
| Q1 2022 | 18.09% |
| Q4 2021 | -77.57% |
| Q3 2021 | 125.27% |
| Q2 2021 | -45.45% |
| Q1 2021 | 124.34% |
| Q4 2020 | 198.06% |
| Q3 2020 | -5.44% |
| Q2 2020 | -1436.36% |
| Q1 2020 | -99.72% |
| Q4 2019 | 3071.43% |
| Q3 2019 | -18.18% |
| Q2 2019 | -63.68% |
| Q1 2019 | 9.84% |
| Q4 2018 | -10.65% |
| Q3 2018 | -22.16% |
| Q2 2018 | 86.24% |
| Q1 2018 | 148.46% |
| Q4 2017 | -317.31% |
| Q3 2017 | 93.84% |
| Q2 2017 | -49.66% |
| Q1 2017 | 133.87% |
| Q4 2016 | -45.61% |
| Q3 2016 | 210.14% |
| Q2 2016 | -202.48% |
| Q1 2016 | 242.25% |